18.4 Systemic Therapy for Advanced & Metastatic Melanoma

18.4 Systemic Therapy for Advanced & Metastatic Melanoma

Molecular Landscape & Actionable Oncogenic Drivers

The treatment landscape of advanced cutaneous melanoma is guided by comprehensive genomic profiling. The major driver mutations are predominantly mutually exclusive and cluster within the mitogen-activated protein kinase (MAPK) signaling pathway (RAS–RAF–MEK–ERK), which regulates cell cycle progression, survival, and proliferation.

Extracellular Growth Factors / RTKs (c-KIT)
                      │
                      ▼
                    RAS (NRAS / NF1-regulated)
                      │
                      ▼
                    RAF (BRAF V600E/K)  <── Target of Dabrafenib / Encorafenib / Vemurafenib
                      │
                      ▼
                    MEK1/2              <── Target of Trametinib / Binimetinib / Cobimetinib
                      │
                      ▼
                    ERK1/2
                      │
                      ▼
  Nuclear Transcription Factors (Cyclin D1, c-Myc) ──> Cell Survival & Proliferation

1. BRAF Mutations

• Epidemiology: Occur in 40% to 50% of cutaneous melanomas, most commonly in younger patients on intermittently sun-exposed skin (trunk and limbs, low-CSD).
• Genomic Architecture:
  • V600E (~80–90%): A point mutation in exon 15 resulting in a single amino acid substitution of valine by glutamic acid at codon 600 (c.1799T>A). This inserts a negatively charged residue that mimics regulatory phosphorylation, locking the kinase domain in an active conformation that signals as an autonomous monomer independently of upstream RAS activation.
  • V600K (~10–20%): Valine replaced by lysine (c.1798_1799delinsAA); more common in older individuals with higher cumulative solar elastosis.
  • Rare Variants (<5%): V600D, V600R, and non-V600 mutations (e.g., L597, K601).
• Clinical Mandate: Testing for BRAF V600 mutations is mandatory in all European patients with high-risk resected Stage III, Stage IV, or unresectable disease using certified molecular assays (next-generation sequencing [NGS], real-time PCR) or VE1 immunohistochemistry (specific for V600E).

2. NRAS Mutations

• Epidemiology: Present in 15% to 20% of cutaneous melanomas; typically mutually exclusive with BRAF mutations.
• Characteristics: Predominantly codon 61 mutations (Q61R, Q61K, Q61L) located in exon 3, which impair intrinsic GTPase activity and maintain NRAS in a permanent GTP-bound active state. Actively signals through both the MAPK and PI3K–AKT–mTOR cascades.
• Therapeutic Implications: Direct pharmacological inhibition of NRAS remains clinically challenging. First-line systemic therapy for NRAS-mutant advanced melanoma is immune checkpoint blockade.

3. KIT Alterations

• Epidemiology: Found in 10% to 15% of acral lentiginous melanomas and 15% to 20% of mucosal melanomas (rare in common cutaneous melanoma, <2%).
• Alterations & Therapy: Includes point mutations (predominantly in exon 11 [e.g., L576P] and exon 13 [e.g., K642E]) and high-level gene amplifications. Tumors harboring exon 11 and 13 mutations demonstrate meaningful clinical responses to receptor tyrosine kinase inhibitors such as imatinib or nilotinib.

4. NF1 (Neurofibromin 1) Alterations

• Characteristics: Inactivating, loss-of-function mutations in NF1 occur in 10% to 15% of cutaneous melanomas, predominantly in elderly patients with chronic sun-damaged skin (high-CSD) and desmoplastic melanomas. NF1 encodes a GTPase-activating protein (GAP) that negatively regulates RAS by accelerating the hydrolysis of active RAS-GTP to inactive RAS-GDP. Loss of NF1 relieves this brake, triggering hyperactive wild-type RAS signaling.
• Genomic Context: NF1-mutant melanomas possess an exceptionally high tumor mutational burden (TMB) and exhibit high responsiveness to anti-PD-1 immunotherapy.

---

Targeted Therapy Combinations: BRAF + MEK Inhibitors

Historical monotherapy with BRAF inhibitors (vemurafenib or dabrafenib) yielded dramatic initial tumor regressions, but median progression-free survival (PFS) was limited to 6 to 7 months due to acquired resistance.

Mechanism of Paradoxical MAPK Activation and Secondary cSCCs

In BRAF wild-type cells (such as normal keratinocytes harboring occult HRAS mutations), BRAF inhibitors bind to BRAF monomers, promoting transactivation and paradoxical heterodimerization with CRAF (RAF1). This causes paradoxical hyperactivation of downstream MEK and ERK, driving the rapid emergence of cutaneous squamous cell carcinomas (cSCC) and keratoacanthomas in up to 20% to 25% of patients treated with BRAF inhibitor monotherapy.

The Dual-Blockade Solution

Adding a selective MEK inhibitor downstream of RAF completely abolishes paradoxical ERK activation, suppresses the emergence of secondary keratinocytic neoplasms (<2%), delays acquired resistance, and significantly improves objective response rates, PFS, and overall survival (OS).

Approved BRAF + MEK Inhibitor Regimens

Three oral combination regimens are approved across Europe for advanced or unresectable BRAF V600-mutated melanoma:

1. Dabrafenib (150 mg PO BID) + Trametinib (2 mg PO daily)
2. Encorafenib (450 mg PO daily) + Binimetinib (45 mg PO BID)
3. Vemurafenib (960 mg PO BID) + Cobimetinib (60 mg PO daily, 21 days on / 7 days off)

Clinical Response Profile

• Kinetics: Characterized by rapid, high objective response rates (ORR: 65% to 75%), with clinical symptomatic improvement often occurring within 48 to 72 hours. Highly advantageous in patients with extensive tumor burden, rapid disease acceleration, acute visceral compromise, or elevated serum LDH.
• Intracranial Activity: Highly effective in reducing brain metastases; dabrafenib + trametinib achieves intracranial disease control in up to 55% of patients with asymptomatic BRAF-mutated cerebral lesions (COMBI-MB trial).

Distinct Toxicities and Management

---

Immune Checkpoint Inhibitors (ICIs)

Immune checkpoint blockade harnesses the patient's own endogenous adaptive immune system to eradicate melanoma cells by blocking inhibitory receptor-ligand interactions that enforce peripheral immune tolerance and T-cell exhaustion.

   T-Cell Priming Phase (Lymph Node)                      T-Cell Effector Phase (Tumour Microenvironment)
   
        Dendritic Cell                                        Tumour Cell / Macrophage
         [ B7-1 / B7-2 ]                                           [ PD-L1 / PD-L2 ]
               │                                                         │
               ├── Blocked by IPILIMUMAB                                 ├── Blocked by NIVOLUMAB / PEMBROLIZUMAB
               ▼                                                         ▼
            [ CTLA-4 ]                                                [ PD-1 ]
            T-Cell Surface                                            T-Cell Surface
   (De-represses T-Cell Priming)                             (Restores Cytotoxic Killing & Clears Exhaustion)

1. Mechanisms of Action

• Anti-PD-1 Antibodies (Nivolumab, Pembrolizumab): Programmed Cell Death Protein 1 (PD-1) is an inhibitory receptor expressed on activated, antigen-experienced CD8+ T lymphocytes. Binding to its ligands (PD-L1 and PD-L2) on tumor cells or tumor-associated macrophages suppresses T-cell receptor (TCR) signaling, dampening cytolytic granule release and inducing functional exhaustion. Monoclonal IgG4 antibodies (nivolumab, pembrolizumab) bind PD-1 with high affinity, blocking ligand engagement and restoring robust anti-tumor cytotoxicity.
• Anti-CTLA-4 Antibody (Ipilimumab): Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4) is expressed on T cells and functions during the initial priming phase within regional lymph nodes. CTLA-4 outcompetes the co-stimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, transmitting an inhibitory signal. Ipilimumab (a human IgG1 monoclonal antibody) blocks CTLA-4, allowing CD28-B7 costimulation to drive polyclonal T-cell activation and depleting immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment.
• Anti-LAG-3 Antibody (Relatlimab): Lymphocyte-Activation Gene 3 (LAG-3) is another distinct inhibitory receptor expressed on exhausted T cells that binds MHC class II. The fixed-dose combination of Nivolumab + Relatlimab demonstrated superior PFS compared to nivolumab monotherapy in the landmark RELATIVITY-047 trial, establishing a third validated checkpoint pathway in Europe.

2. Clinical Efficacy & The CheckMate-067 Landmark Trial

The phase III CheckMate-067 trial fundamentally redefined survival benchmarks in unresectable or metastatic cutaneous melanoma:

• Nivolumab + Ipilimumab (Dual Blockade):
  • Achieved a median overall survival of about 72 months (71.9 months in the 10-year analysis), compared with 36.9 months for nivolumab monotherapy and 19.9 months for ipilimumab monotherapy.
  • Long-Term Overall Survival: 52% at 5 years, 48% at 7.5 years, and 43% at 10 years with the combination; melanoma-specific survival curves plateau, consistent with long-term disease control in many patients.
  • Toxicity: Grade 3 or 4 treatment-related adverse events occurred in 55% to 59% of patients receiving combination therapy, compared to 21% with nivolumab monotherapy and 28% with ipilimumab monotherapy.

---

Immune-Related Adverse Events (irAEs) Management Protocols

Unchecked immune activation can trigger inflammatory autoimmune toxicities in any organ system. Early recognition, rigorous grading according to the Common Terminology Criteria for Adverse Events (CTCAE), and swift immunosuppressive intervention are essential to prevent life-threatening complications.

Clinical Spectrum of irAEs

1. Gastrointestinal (Colitis / Enteritis):
   • Symptoms: Frequent watery diarrhea, abdominal cramping, hematochezia, fever, peritoneal signs.
   • Classification: Grade 1 (<4 stools/day above baseline); Grade 2 (4–6 stools/day); Grade 3–4 (≥7 stools/day, fecal incontinence, peritoneal signs, bowel perforation, hemodynamic collapse).
   • Diagnostic Workup: Stool studies to exclude infectious colitis (Clostridioides difficile, CMV, bacterial pathogens), flexible sigmoidoscopy/colonoscopy with biopsy.
2. Hepatic (Immune-Mediated Hepatitis):
   • Presentation: Typically asymptomatic elevation of serum transaminases (AST, ALT) and total bilirubin; detected on routine pre-infusion laboratory screening.
3. Endocrine Toxicities:
   • Hypophysitis (Pituitaryitis): Predominantly triggered by CTLA-4 blockade (ipilimumab, dual therapy). Symptoms: severe persistent frontal headache, extreme fatigue, visual disturbances, orthostatic dizziness, and nausea. Laboratory findings demonstrate central adrenal insufficiency (low morning cortisol with inappropriately low ACTH), central hypothyroidism (low free T4 with low/normal TSH), and low sex steroids. Pituitary MRI demonstrates diffuse infundibular thickening and pituitary gland enlargement. Crucially, anterior pituitary function rarely recovers, mandating lifelong physiologic hormone replacement (oral hydrocortisone, levothyroxine).
   • Thyroiditis: Highly common with anti-PD-1 agents. Presents initially with transient painless thyrotoxicosis (suppressed TSH, elevated free T4) lasting 2 to 6 weeks, which rapidly transitions into permanent primary hypothyroidism (elevated TSH, low free T4). Does not require corticosteroids; managed seamlessly with daily oral levothyroxine while continuing immunotherapy.
   • Type 1 Diabetes Mellitus: Rapid-onset acute ketoacidosis with low or absent C-peptide due to acute autoimmune destruction of pancreatic beta cells; requires immediate insulin therapy.
4. Pulmonary (Pneumonitis):
   • Symptoms: Non-productive cough, progressive dyspnea, exercise intolerance, hypoxemia. High-resolution chest CT shows ground-glass opacities, cryptogenic organizing pneumonia, or interstitial infiltrates.
5. Cardiac (Immune Myocarditis):
   • Clinical Significance: Rare (<1%), but carries a case fatality rate approaching 30% to 50%. Presents with chest pain, acute arrhythmias, heart failure, or sudden cardiogenic collapse. Diagnostic findings include elevated high-sensitivity troponin, abnormal ECG, and cardiac MRI demonstrating myocardial edema. Requires immediate transfer to an intensive care unit and pulse-dose intravenous methylprednisolone (1000 mg/day).
6. Cutaneous Toxicities and the Vitiligo Biomarker:
   • Common: Pruritus, morbilliform maculopapular rash, lichenoid eruptions, and psoriasiform flares.
   • Vitiligo-Like Depigmentation: Characterized by patchy, well-demarcated symmetrical milky-white depigmented macules and patches occurring predominantly on sun-exposed extremities and face. Pathophysiologically, it results from cross-reactive cytotoxic CD8+ T cells targeting melanocyte differentiation antigens shared between neoplastic melanoma cells and normal cutaneous melanocytes (e.g., Melan-A/MART-1, tyrosinase, gp100).
   • High-Yield Clinical Pearl: The emergence of vitiligo is never a reason to stop immunotherapy; it represents an on-target autoimmune biological marker that strongly correlates with superior objective tumor response, prolonged progression-free survival, and extended overall survival.

Protocolized irAE Management Escalation

                                  irAE Severity Classification & Escalation
                                                      │
        ┌───────────────────────────────┬─────────────┴─────────────┬───────────────────────────────┐
        ▼                               ▼                           ▼                               ▼
     Grade 1                         Grade 2                     Grade 3                         Grade 4
 (Mild, asymptomatic)          (Moderate symptoms)          (Severe symptoms)             (Life-threatening)
        │                               │                           │                               │
        ▼                               ▼                           ▼                               ▼
- Continue Immunotherapy       - Withhold Immunotherapy     - Permanently Discontinue*    - Permanently Discontinue
- Symptomatic treatment        - Oral Prednisone            - Hospitalise Patient         - Immediate Hospitalisation / ICU
  (topicals, loperamide)         (0.5 to 1.0 mg/kg/day)     - IV Methylprednisolone       - IV Methylprednisolone
- Close clinical monitoring    - Resume when Grade <=1        (1.0 to 2.0 mg/kg/day)        (1.0 to 2.0 mg/kg or 1g pulse)
                                 and steroids <=10 mg       - Taper over >=4–6 weeks      - Taper over >=6–8 weeks

• Grade 1: Continue immunotherapy with frequent clinical and laboratory monitoring (exceptions: myocarditis, neurological toxicities, or severe bullous dermatoses, which mandate immediate treatment cessation even at Grade 1).
• Grade 2: Withhold checkpoint inhibitor therapy. Initiate oral prednisone at 0.5 to 1.0 mg/kg/day. Immunotherapy may be resumed once symptoms improve to Grade ≤1 and corticosteroid dose is successfully tapered to ≤10 mg/day.
• Grade 3–4: Permanently discontinue immunotherapy (selected exceptions: isolated endocrine toxicities managed with hormone replacement). Immediately hospitalize the patient and initiate high-dose systemic corticosteroids: intravenous methylprednisolone 1.0 to 2.0 mg/kg/day (or oral prednisone equivalent). Corticosteroids must be tapered slowly over at least 4 to 6 weeks to prevent rebound flares.
• Steroid-Refractory Management (No Improvement within 48 to 72 Hours):
  • Steroid-Refractory Immune Colitis: Administer Infliximab (5 mg/kg IV), a chimeric anti-TNF-alpha monoclonal antibody; a second dose may be administered at 2 weeks. Alternatively, vedolizumab (anti-α4β7 integrin) may be utilized.
  • Steroid-Refractory Immune Hepatitis: INFLIXIMAB IS STRICTLY CONTRAINDICATED due to the high risk of fatal acute hepatic necrosis. Instead, steroid-refractory hepatitis is managed with Mycophenolate Mofetil (MMF, 1000 mg PO BID) or antithymocyte globulin (ATG).

---

Adjuvant & Neoadjuvant Systemic Therapy

1. Adjuvant Systemic Therapy (Completely Resected High-Risk Melanoma)

• Indications: Recommended after complete resection of Stage III disease (macroscopic or micrometastatic nodal involvement, or satellite/in-transit lesions) and completely resected Stage IV disease. Pembrolizumab (KEYNOTE-716) and nivolumab (CheckMate 76K) are also EU-approved as adjuvant therapy for resected stage IIB/IIC melanoma.
• Standard European Regimens (Administered for a Planned Duration of 12 Months):
  1. Nivolumab Monotherapy (Anti-PD-1): CheckMate-238 trial established significant improvement in recurrence-free survival (RFS) compared to high-dose ipilimumab, with vastly superior tolerability.
  2. Pembrolizumab Monotherapy (Anti-PD-1): KEYNOTE-054 trial demonstrated significant prolongation of RFS compared to placebo across Stage IIIA, IIIB, and IIIC disease.
  3. Dabrafenib + Trametinib (BRAF/MEK Inhibitor Dual Therapy): COMBI-AD trial demonstrated sustained 5-year RFS and overall survival benefits in completely resected BRAF V600E/K mutant Stage III melanoma.
• Clinical Selection Strategy in BRAF-Mutant Stage III: Both anti-PD-1 monotherapy and dabrafenib + trametinib are validated European first-line adjuvant options. Targeted therapy offers oral administration and avoids irreversible autoimmune endocrinopathies, but carries daily pill burden and pyrexia risk. Anti-PD-1 therapy involves intravenous infusions every 3 to 6 weeks and generates durable immune memory, but carries a small risk of permanent endocrine or neurological irAEs.

2. Neoadjuvant Systemic Therapy (Resectable Macroscopic Stage III/IV)

Neoadjuvant therapy—administering systemic treatment prior to surgical lymphadenectomy in patients with macroscopic, clinically detectable resectable regional metastases—has rapidly emerged as a superior oncological approach:

• Biological Rationale: Administering immune checkpoint blockade while the bulk of the tumor and intact regional lymph nodes are present in situ allows dendritic cells to expose the host immune repertoire to a vast array of native tumor neoantigens. This primes a substantially broader, highly polyclonal anti-tumor T-cell response compared to adjuvant administration after surgical removal of the tumor and lymph node basin.
• The NADINA Trial (2024 Landmark Study):
  • Compared neoadjuvant Nivolumab 240 mg + Ipilimumab 80 mg for two cycles (every 3 weeks) followed by surgery, versus upfront surgery followed by 12 months of adjuvant nivolumab, in resectable macroscopic Stage III melanoma.
  • Landmark Results: Neoadjuvant therapy produced a major pathological response (complete or near-complete) in 59% of patients. At 12 months, event-free survival (EFS) was 83.7% in the neoadjuvant arm versus 57.2% in the adjuvant arm.
  • Response-Adapted De-escalation: Patients with a major pathological response had no further adjuvant therapy, sparing them months of drug exposure; non-responders received adjuvant treatment.